Literature DB >> 17155906

The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity.

Laurent Rivory1, Carly Tucker, Andrew King, Angela Lai, Amber Goodchild, Craig Witherington, Mary Margaret Gozar, Donald J Birkett.   

Abstract

DNAzymes are catalytic DNA molecules capable of cleaving RNA substrates and therefore constitute a possible gene-suppression technology. We examined whether the previously reported potency of a DNAzyme targeting c-jun (Dz13) could be improved with judicious use of sequence and chemical modifications. Catalytic activity was measured to establish correlations between catalytic activity and biological potency. Surprisingly, Dz13 had significant cytotoxic activity against cells of rodent origin (IC(50) = 20-50 nM) despite having greatly reduced catalytic activity against a rodent target substrate (<25%), the latter being the result of a mismatch to the rodent c-jun sequence. In contrast, a modified Dz13 matching the rodent c-jun sequence (DT1501b) had no activity at similar concentrations against human or rodent cells despite being able to efficiently cleave the rodent c-jun sequence. Overall, catalytic activity against synthetic substrates did not correlate with cytotoxic activity and catalytically inactive mutants had in some cases equal or superior potency in cell cytotoxicity assays. Further examination of other previously published DNAzymes (Rs6 and DzF) revealed other occurrences of this anomalous behaviour. The active sequences all have G-rich 5 termini, suggesting that G-quadruplex formation might be involved. Consistent with this, deaza-guanosine substitutions abrogated cytotoxicity of Dz13. However, Dz13 did not show evidence of quadruplex formation as determined by circular dichroism studies and native electrophoresis. These data reveal that the biologic activity of several published DNAzymes is not mediated through the catalytic degradation of target mRNA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17155906     DOI: 10.1089/oli.2006.16.297

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  5 in total

Review 1.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors:  Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 2.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

3.  A modular XNAzyme cleaves long, structured RNAs under physiological conditions and enables allele-specific gene silencing.

Authors:  Alexander I Taylor; Christopher J K Wan; Maria J Donde; Sew-Yeu Peak-Chew; Philipp Holliger
Journal:  Nat Chem       Date:  2022-09-05       Impact factor: 24.274

4.  Targeting non-coding RNA family members with artificial endonuclease XNAzymes.

Authors:  Maria J Donde; Adam M Rochussen; Saksham Kapoor; Alexander I Taylor
Journal:  Commun Biol       Date:  2022-09-24

5.  Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif.

Authors:  Amber Goodchild; Andrew King; Mary Margaret Gozar; Toby Passioura; Carly Tucker; Laurent Rivory
Journal:  Nucleic Acids Res       Date:  2007-06-22       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.